COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,250 Articles (22,733 medRxiv, 8,517 bioRxiv)

Most recent first Previous |  Page 525: Articles 5241-5250  | Next

Genomic characterization and molecular evolution of SARS-CoV-2 in Rio Grande do Sul State, Brazil
Mayer, A. M., Ferrareze, P. A. G., de Oliveira, L. F. V., Gregianini, T. S., Neves, C. L. A. M., Caldana, G. D., Kmetzsch, L., Thompson, C. E.
10.1101/2023.01.02.23284121 — Posted: 2023-01-04
A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years
Gunale, B., Kapse, D., Kar, S., Bavdekar, A., Kohli, S., Lalwani, S., Meshram, S., Raut, A., Kulkarni, P., Samuel, C., Munshi, R., Gupta, M., Plested, J. S., Cloney-Clarke, S., Zhu, M., Pryor, M., Hamilton, S., Thakar, M., Shete, A., Dharmadhikari, A., Bhamare, C., Shaligram, U., Poonawalla, C. S., Mallory, R. M., Glenn, G. M., Kulkarni, P. S., COVOVAX-Ped Study Group
10.1101/2023.01.03.23284130 — Posted: 2023-01-04
The time between vaccination and infection impacts immunity against SARS-CoV-2 variants
Bates, T. A., Leier, H. C., McBride, S. K., Schoen, D., Lyski, Z. L., Lee, D. X., Messer, W. B., Curlin, M. E., Tafesse, F. G.
10.1101/2023.01.02.23284120 — Posted: 2023-01-04
Participant Demographics and Testing Trends: A Community Pandemic Response Program
Garcia, Y. E., Solis, L., Daza-Torres, M. L., Montesinos-Lopez, J. C., Pollock, B. H., Nuno, M.
10.1101/2023.01.02.23284119 — Posted: 2023-01-04
Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy
de Meijere, G., Valdano, E., Castellano, C., Debin, M., Kengne-Kuetche, C., Turbelin, C., Noël, H., Weitz, J. S., Paolotti, D., Hermans, L., Hens, N., Colizza, V.
10.1101/2022.12.30.22283726 — Posted: 2023-01-04
Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1
Tsui, L. H., Lambert, B., Bajaj, S., McCrone, J. T., Inward, R. P. D., Bosetti, P., Hill, V., Pena, R. E., Zarebski, A. E., Peacock, T. P., Liu, L., Wu, N., Davis, M., Bogoch, I. I., Khan, K., Colquhoun, R., O'Toole, A., Jackson, B., Dasgupta, A., Wilkinson, E., Tegally, H., de Oliveira, T., The COVID-19 Genomics UK (COG-UK) consortium, , Connor, T. R., Loman, N. J., Colizza, V., Fraser, C., Volz, E., Ji, X., Suchard, M. A., Gutierrez, B., Chand, M., Dellicour, S., Cauchemez, S., Raghwani, J., Lemey, P., Rambaut, A., Pybus, O. G., Kraemer, M. U. G.
10.1101/2023.01.02.23284109 — Posted: 2023-01-04
Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies
Lan, S., Neilsen, G., Slack, R. L., Cantara, W. A., Emanuelli Castaner, A., Lorson, Z. C., Lulkin, N. D., Zhang, H., Lee, J., Cilento, M. E., Tedbury, P. R., Sarafianos, S. G.
10.1101/2022.12.31.522389 — Posted: 2023-01-03
L-shape distribution of the relative substitution rate (c micro) observed for SARS-COV-2 genome, inconsistent with the selectionist theory, the neutral theory and the nearly neutral theory but a near-neutral balanced selection theory: implication on neutralist-selectionist debate
Wu, C., Paradis, N., Lakernick, P., Hryb, M.
10.1101/2023.01.01.522435 — Posted: 2023-01-03
Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion
Yue, C., Song, W., Wang, L., Jian, F., Chen, X., Gao, F., Shen, Z., Wang, Y., Wang, X., Cao, Y. R.
10.1101/2023.01.03.522427 — Posted: 2023-01-03
Nanoparticle-Conjugated TLR9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines
Ou, B. S., Picece, V. C. T. M., Baillet, J., Gale, E. C., Powell, A. E., Saouaf, O. M., Yan, J., Lopez Hernandez, H., Appel, E.
10.1101/2023.01.02.522505 — Posted: 2023-01-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).